Facing donor shortages and storage limitations, researchers are developing synthetic red blood cells, platelets, and plasma and combining them into artificial blood.
A biopharmaceutical company established a new method for isolating and editing hematopoietic stem cells from patients to provide stem cell therapies for diseases such as sickle cell disease.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.